On August 23, 2021, 17 of the 22 members on the Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted “Yes” in favor of the FDA’s approval of Pfizer’s mRNA COVID-19 vaccine, proprietary name: Comirnaty. [1] Eight days later, the director of the FDA’s Office of Vaccines Research and Review (OVRR), Dr. Marion Gruber announced…